Trial Profile

A phase 2 study of LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopregnanolone prodrug (Primary)
Indications Fragile X tremor ataxia syndrome
Focus Therapeutic Use

Most Recent Events

14 Nov 2023 According to a PureTech Health Media Release, this trial is expected to initiate in 2024.
08 Aug 2023 New trial record
01 Aug 2023 According to a PureTech Health Media Release, Dr. Randi Hagerman, M.D. is a co-primary investigator for the LYT-300 trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com